Three New Tools Accelerate the Study of Intact Proteins and Peptide Mapping: BioPharmaView™ Software, the TripleTOF® 6600 System, and SWATH® Acquisition 2.0
Framingham, MA — SCIEX, a global leader in life science analytical technologies, today introduced its latest additions to a growing line of solutions for the characterization of biotherapeutics such as monoclonal antibodies and emerging protein classes at both the intact protein and peptide levels. These solutions - TripleTOF 6600 system with SWATH® and BioPharmaView - are ideal for studying changes in biotherapeutics and help researchers gain rapid, accurate, and confident understanding of compounds in this area of drug development.
BioPharmaView Software is a powerful new product for automating core workflows, offering exceptional investigative capabilities and fast data acquisition. Built on customer feedback, BioPharmaView Software can efficiently analyze and compare batches while monitoring critical quality attributes according to the FDA's well-characterized biotherapeutic product (WCBP) model.
The TripleTOF 6600 high-resolution, accurate-mass system brings new power to scientists developing biotherapeutics. Delivering the broad mass and dynamic range required for these compounds, the new instrument offers the unique ability to address biomolecules and their complexities quickly and easily. Together, the TripleTOF 6600 system and BioPharmaView software deliver accurate assay information for protein digests, in a simplified view. The software is designed with a deconvolution feature that allows for comparisons of end results to "gold standard" spectra to determine product quality, making it smarter and more efficient.
SWATH® Acquisition 2.0 allows researchers to develop simple, universal assays that ensure complete information coverage of their analytes in a fast and automated workflow. Combined with the increased dynamic range of the TripleTOF 6600 System, SWATH® 2.0 enables researchers to achieve deeper insight into complex samples.
"The new innovations we are bringing to biologics will improve our customers' ability to reduce costs and decrease drug development time to market through automated workflows, better assay information, and increased confidence in identification" commented Joseph Fox, Senior Director, of the Pharmaceutical and CRO Business Unit at SCIEX.